AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00145600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 cycles of VAMP chemotherapy
Description: 4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
Study NCT00145600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 alternating cycles of VAMP/COP chemotherapy
Description: 2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
Study NCT00145600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 alternating cycles of VAMP/COP chemotherapy
Description: 3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
Study NCT01071473 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 12 Week Exercise Intervention
Description: Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
Study NCT03051646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit
Description: 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
Study NCT03051646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit
Description: Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
Study NCT03490968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: Subjects will have 3 visits per week for 12 weeks.
Study NCT06697652 — intervention group
Intervention type: PROCEDURE
Intervention: adrenalectomy
Description: adrenalectomy
Study NCT01570777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal denervation and optimized medication regimen
Description: Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
Study NCT01570777 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: optimized medication regimen
Description: Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
Study NCT02954718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity training
Study NCT02500927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8273 Capsules
Description: oral
Study NCT02500927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8273 Capsules A
Description: oral
Study NCT02442544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: 1:1 oligofructose: inulin 8 g orally /day
Study NCT02442544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltodextrin 3.3g orally/day
Study NCT03553862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: collaborative care
Description: The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.nurses and dietitians as well as a pharmacist.
Study NCT04003974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod oral tablet
Description: Losmapimod will be administered with food when possible.
Study NCT04003974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be administered with food when possible
Study NCT03490968 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vascular Assessment
Description: Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated.
Study NCT04145297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles
Study NCT02705326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opti-Speech
Description: Uses visual feedback of the tongue's motion to guide speech sound production
Study NCT03941795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS001(Toripalimab Injection)
Description: Test Group:~Toripalimab (240 mg, IV, Q3W) + axitinib (5 mg/tablet, one tablet, twice a day, orally); axitinib is started on the second day of administration of toripalimab until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of toripalimab use of no more than 2 years.
Study NCT03941795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib 1 MG [Inlyta]
Description: Axitinib (5 mg/tablet) one tablet, twice a day, orally until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death
Study NCT03941795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JS001 and Axitinib
Description: Control Group:~Toripalimab (240 mg, IV, Q3W) is administered on the first day until disease progression or intolerable toxicity, the investigator or subject decides to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death, with a maximum duration of no more than 2 years
Study NCT04469400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fat diet intensive intervention
Description: education and Compound protein solid beverage
Study NCT04469400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Carbon Water Diet Intensive Intervention
Description: education and Nutrition bar
Study NCT03144479 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: right-sided double lumen tube
Description: Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
Study NCT00496067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler-Guided Uterine Artery Occlusion Device
Description: For bilateral occlusion of the uterine arteries
Study NCT04598607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypidone Hydrochloride tablets
Description: 30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.
Study NCT00742274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore TAG Endoprosthesis
Description: Implant Gore TAG device with Best Medical therapy per physician discretion
Study NCT00742274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Therapy
Description: Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
Study NCT04531683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: same as described in experimental arm.
Study NCT04531683 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: same as described in sham comparator.
Study NCT04531683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: life style counselling
Description: life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
Study NCT04531683 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: life style counselling
Description: life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
Study NCT04531683 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: life style counselling
Description: life style counselling to patients with mixed urinary incontinence contains advice on daily drinking, caffeine intake, diet, constipation, exercise, heavy lifting, lung disease, urinary track infection and etc.
Study NCT02861261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder
Description: 1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night
Study NCT02861261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Berberine placebo tablets ; 2. ProMetS probiotics powder
Description: 1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 4g (2 strips) of ProMetS probiotics powder administered orally every night
Study NCT02861261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Berberine hydrochloride tablets; 2. Probiotics placebo powder
Description: 1. 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night
Study NCT02861261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1. Berberine placebo tablets; 2. Probiotics placebo powder
Description: 1. 6 pills of Berberine placebo tablets administered twice a day orally before meal;~2. 2 strips of probiotics placebo powder administered orally every night
Study NCT02444442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Denervation
Description: Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
Study NCT02444442 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Arterial access only. No delivery of radio frequency energy to renal arteries.
Study NCT04471987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL12-L19L19
Description: Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28).~Part II - Dose expansion: Once the dose escalation is completed, additional 40 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications.
Study NCT04471987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL12-L19L19
Description: Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.
Study NCT02511561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201 (ciprofloxacin)
Study NCT03490968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vascular Assessment
Description: Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated.
Study NCT03490968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vascular Assessment
Description: Screen: Subjects will undergo a H\&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg revascularization patients will return in 12 weeks and have the same study procedures as testing visit 1, plus an ankle brachial index, repeated.
Study NCT03395925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celon Pro Surge
Description: bipolar coagulation electrode intended for tissue heating
Study NCT01218633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: saline infused at 30ml/hour
Study NCT01218633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1-9,36 infusion
Description: infused @ 1.2pmol/kg/min
Study NCT04145297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
Study NCT01218633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39 at low dose
Description: infused at 30pmol/kg/min
Study NCT01218633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-9,39 at high dose
Description: infused @ 300pmol/kg/min
Study NCT03395054 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cervical stabilization exercises
Description: cervical stabilization exercises
Study NCT03395054 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional exercises
Description: conventional exercises
Study NCT04282512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-rich mineral water
Description: St-Yorre, a sodium bicarbonate-rich mineral water, is a commercial mineral water that contains 4368 mg/l sodium bicarbonate. The study intends to evaluate the effect on blood pressure of the sodium bicarbonate intake due to this mineral water consumption.
Study NCT00633620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)
Description: colonoscopy withdrawal with NBI mode
Study NCT01266941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled FF 200mcg/GW642444M 25mcg
Description: All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
Study NCT04598607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
Study NCT04541680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 MG [Ofev]
Description: Experimental group will receive nintedanib 150mg BID for 12 months in addition to standard of care (SoC). Nintedanib dose could be reduced to 100mg BID depending on tolerance according to investigator in charge of the patient. The prescription of SoC drugs or procedure will be let to the choice of the investigator in charge of the patient.
Study NCT04541680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03247699 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basel phenotyping cocktail capsule
Description: Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling
Study NCT03247699 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basel phenotyping cocktail individual components
Description: Oral intake of Basel phenotyping cocktail individual components and PK sampling
Study NCT00147914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefdinir (drug)
Description: cefdinir 300mg per orally twice daily for 10 days
Study NCT00147914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin/clavulanate
Description: 1000mg /62.5mg extended release per orally twice daily for 10 days
Study NCT04112368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal Patch 0.1 mg/24 hrs
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
Study NCT04112368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol Transdermal Patch 0.1 mg/24 hrs
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
Study NCT04112368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone 200mg
Description: 100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)
Study NCT04112368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Micronized Progesterone 200mg
Description: 100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)
Study NCT04112368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive Clear Patch
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
Study NCT04112368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Clear Patch
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
Study NCT04112368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Study NCT04112368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Study NCT01278537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Booklet, motivational interviewing, brief advice
Study NCT00002569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Study NCT00002569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Study NCT00002569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00002569 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00002569 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT03908242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvianolic acid A
Description: salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
Study NCT03908242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
Study NCT02987829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC253
Description: TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR. TRC253 blocks AR nuclear translocation as well as AR binding to DNA and is an antagonist of transcription for wild type AR and mutated AR. TRC253 is orally active and does not have agonist activity towards either the wild type or mutated ARs. TRC253 treatment in the Hershberger assay results in complete inhibition of androgen sensitive organ development. TRC253 is efficacious in an LNCaP xenograft model driven by F876L (also known as F877L) mutant AR.